Free Trial
NYSE:AIM

AIM ImmunoTech (AIM) Stock Price, News & Analysis

AIM ImmunoTech logo
$2.70 +0.01 (+0.37%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$2.67 -0.03 (-1.11%)
As of 08/22/2025 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About AIM ImmunoTech Stock (NYSE:AIM)

Key Stats

Today's Range
$2.54
$2.75
50-Day Range
$2.36
$10.42
52-Week Range
$2.33
$39.00
Volume
71,785 shs
Average Volume
66,661 shs
Market Capitalization
$2.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$275.00
Consensus Rating
Buy

Company Overview

AIM ImmunoTech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
23rd Percentile Overall Score

AIM MarketRank™: 

AIM ImmunoTech scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AIM ImmunoTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    AIM ImmunoTech has received no research coverage in the past 90 days.

  • Read more about AIM ImmunoTech's stock forecast and price target.
  • Earnings Growth

    Earnings for AIM ImmunoTech are expected to decrease in the coming year, from ($0.30) to ($0.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AIM ImmunoTech is -5.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AIM ImmunoTech is -5.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    AIM ImmunoTech has a P/B Ratio of 13.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for AIM.
  • Dividend Yield

    AIM ImmunoTech does not currently pay a dividend.

  • Dividend Growth

    AIM ImmunoTech does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for AIM.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for AIM ImmunoTech this week, compared to 2 articles on an average week.
  • Search Interest

    11 people have searched for AIM on MarketBeat in the last 30 days.
  • MarketBeat Follows

    5 people have added AIM ImmunoTech to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AIM ImmunoTech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.02% of the stock of AIM ImmunoTech is held by insiders.

  • Percentage Held by Institutions

    Only 12.02% of the stock of AIM ImmunoTech is held by institutions.

  • Read more about AIM ImmunoTech's insider trading history.
Receive AIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter.

AIM Stock News Headlines

AIM ImmunoTech releases CEO Corner segment
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
See More Headlines

AIM Stock Analysis - Frequently Asked Questions

AIM ImmunoTech's stock was trading at $19.80 at the beginning of 2025. Since then, AIM shares have decreased by 86.4% and is now trading at $2.70.

AIM ImmunoTech Inc. (NYSE:AIM) released its quarterly earnings results on Wednesday, November, 15th. The company reported ($16.00) earnings per share for the quarter, missing analysts' consensus estimates of ($11.00) by $5.00. The business earned $0.05 million during the quarter. AIM ImmunoTech had a negative net margin of 12,594.21% and a negative trailing twelve-month return on equity of 421.73%.

Shares of AIM ImmunoTech reverse split before market open on Thursday, June 12th 2025.The 1-100 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Top institutional investors of AIM ImmunoTech include Corient Private Wealth LLC (1.31%). Insiders that own company stock include Thomas K Equels, Peter W Rodino III, Stewart Appelrouth and Nancy Bryan.
View institutional ownership trends
.

Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), iBio (IBIO), Vaxart (VXRT), Meta Platforms (META), Sorrento Therapeutics (SRNE), NIO (NIO) and T2 Biosystems (TTOO).

Company Calendar

Last Earnings
11/15/2023
Today
8/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:AIM
CIK
946644
Employees
20
Year Founded
1990

Price Target and Rating

High Price Target
$450.00
Low Price Target
$100.00
Potential Upside/Downside
+10,085.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($24.68)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$28.96 million
Net Margins
-12,594.21%
Pretax Margin
-12,594.21%
Return on Equity
-421.73%
Return on Assets
-147.54%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
0.75
Quick Ratio
0.75

Sales & Book Value

Annual Sales
$121 thousand
Price / Sales
17.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.20 per share
Price / Book
13.50

Miscellaneous

Outstanding Shares
764,000
Free Float
68,740,000
Market Cap
$2.06 million
Optionable
Not Optionable
Beta
0.88

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NYSE:AIM) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners